Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.47 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 10/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964998 | 0.89 | PIM2 (0.47) | PRKCAPRKCQPRKCDPIM2CHRNB2 | |
| SCHEMBL8965888 | 0.88 | PRKCA (0.51) | PRKCAPRKCQPRKCDPIM2HSD17B14 | |
| SCHEMBL8965021 | 0.88 | PIM2 (0.52) | PRKCAPRKCQPRKCDPIM2HSD17B14 | |
| SCHEMBL8964879 | 0.85 | HSD17B14 (0.53) | PRKCAPRKCQPRKCDPIM2HSD17B14 | |
| SCHEMBL8963649 | 0.83 | PRKCA (0.53) | PRKCAPRKCQPRKCDPIM2HSD17B14 | |
| SCHEMBL8965010 | 0.83 | CHRNB2 (0.41) | PRKCAPRKCQPRKCDPIM2CHRNB2 | |
| SCHEMBL8964722 | 0.82 | HSD17B14 (0.43) | PRKCAPRKCQPRKCDPIM2HSD17B14 | |
| SCHEMBL8964909 | 0.82 | PRKCA (0.55) | PRKCAPRKCQPRKCDPIM2HSD17B14 | |
| SCHEMBL8964367 | 0.82 | PRKCA (0.52) | PRKCAPRKCQPRKCDPIM2HSD17B14 | |
| SCHEMBL8965541 | 0.82 | PRKCA (0.52) | PRKCAPRKCQPRKCDPIM2HSD17B14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCA 25/4885PRKCQ 38/4885PRKCD 120/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCA 25/4885PRKCQ 38/4885PRKCD 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.